

# Vincenzo Savarino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/862675/publications.pdf>

Version: 2024-02-01

165  
papers

6,765  
citations

70961

41  
h-index

71532

76  
g-index

165  
all docs

165  
docs citations

165  
times ranked

4792  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials. <i>Digestive and Liver Disease</i> , 2023, 55, 208-222.	0.4	10
2	Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 23-35.	1.1	22
3	Gastroesophageal reflux disease: key messages for clinicians. <i>Minerva Gastroenterology</i> , 2022, 67, .	0.3	4
4	Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210768.	1.4	1
5	Pharmacotherapies in eosinophilic esophagitis: state of the art. <i>Minerva Gastroenterology</i> , 2022, 68, 69-76.	0.3	0
6	Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14416.	1.6	1
7	Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 606-613.	1.9	16
8	Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. <i>Esophagus</i> , 2022, 19, 525-534.	1.0	11
9	Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102264.	1.7	4
10	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1554-1563.	2.4	34
11	Management of Osteoarthritis: Expert Opinion on NSAIDs. <i>Pain and Therapy</i> , 2021, 10, 783-808.	1.5	40
12	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1609-1621.	2.0	21
13	Prevention Strategies for Esophageal Cancer—An Expert Review. <i>Cancers</i> , 2021, 13, 2183.	1.7	19
14	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. <i>Nutrients</i> , 2021, 13, 1630.	1.7	21
15	Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. <i>Cancers</i> , 2021, 13, 3162.	1.7	35
16	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, , 1-10.	1.4	4
17	Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482098086.	1.4	40
18	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Minerva Gastroenterology</i> , 2021, , .	0.3	5

#	ARTICLE	IF	CITATIONS
19	Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux Exposures. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1-7.	0.9	37
20	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2397-2402.	1.1	6
21	A further step forward in our knowledge of the pathogenetic role of gastroesophageal reflux in pulmonary fibrosis. <i>Digestive and Liver Disease</i> , 2020, 52, 986-987.	0.4	1
22	Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2790-2792.e1.	2.0	9
23	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. <i>Digestive and Liver Disease</i> , 2020, 52, 1413-1420.	0.4	16
24	Latest insights into the hot question of proton pump inhibitor safety â€” a narrative review. <i>Digestive and Liver Disease</i> , 2020, 52, 842-852.	0.4	25
25	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. <i>Digestive and Liver Disease</i> , 2020, 52, 862-868.	0.4	11
26	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. <i>Digestive and Liver Disease</i> , 2020, 52, 966-980.	0.4	27
27	Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. <i>Journal of Clinical Medicine</i> , 2020, 9, 2011.	1.0	16
28	The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 311-321.	0.8	26
29	Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13919.	1.6	23
30	&lt;p&gt;Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data&lt;/p&gt;. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 99-104.	1.0	14
31	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 437-449.	1.3	21
32	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohnâ€™s Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 451-456.	0.5	21
33	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. <i>Korean Journal of Family Medicine</i> , 2020, 41, 250-255.	0.4	7
34	Eosinophilic esophagitis and biologics. <i>Minerva Gastroenterology</i> , 2020, , .	0.3	1
35	Gastro-esophageal reflux disease: Key messages for clinicians. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, , .	2.2	4
36	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67	6.1	80

#	ARTICLE	IF	CITATIONS
37	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1011-1012.	1.3	1
38	Updates in the field of non-esophageal gastroesophageal reflux disorder. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 827-838.	1.4	31
39	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , 2019, 67-68, 110542.	1.1	42
40	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1220-1225.	0.6	6
41	<p></p>Idiopathic pulmonary fibrosis and GERD: links and risks</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1081-1093.	0.9	42
42	Advancements in the use of manometry and impedance testing for esophageal functional disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 425-435.	1.4	10
43	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in Crohnâ€™s disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 79-88.	1.4	14
44	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13056.	1.7	30
45	Vonoprazan May Provide Better Results than PPIs in Helicobacter Pylori Eradication and Beyond â€œ Is it Time for a Change?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 375-377.	0.5	1
46	Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. <i>American Journal of Gastroenterology</i> , 2018, 113, 670-676.	0.2	60
47	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 452-456.	0.4	22
48	Psoriasis and small intestine bacterial overgrowth. <i>International Journal of Dermatology</i> , 2018, 57, 112-113.	0.5	21
49	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 569-574.	1.6	5
50	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. <i>Annals of Hepatology</i> , 2018, 17, 830-835.	0.6	25
51	Improvement in WaldenstrÃ¶mâ€™s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. <i>Annals of Hepatology</i> , 2018, 17, 1072-1077.	0.6	3
52	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. <i>Annals of Gastroenterology</i> , 2018, 31, 639-648.	0.4	68
53	Proton pump inhibitors: use and misuse in the clinical setting. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1123-1134.	1.3	112
54	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in nonâ€™erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1074-1081.	1.9	32

#	ARTICLE	IF	CITATIONS
55	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	17
56	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) â€” Study section â€œDigestive Diseases in Primary Careâ€. <i>Digestive and Liver Disease</i> , 2018, 50, 894-902.	0.4	30
57	High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in-vivo evaluation. <i>United European Gastroenterology Journal</i> , 2018, 6, 981-989.	1.6	55
58	A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 785-794.	1.0	24
59	Reduction in <sc>TIMP</sc>â€” serum levels predicts remission of inflammatory bowel diseases. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13002.	1.7	13
60	Effects of bariatric surgery on the esophagus. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 243-248.	1.0	12
61	The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , 2018, 109, 386-399.	0.3	46
62	Improvement in WaldenstrÃ¶mâ€™s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. <i>Annals of Hepatology</i> , 2018, 17, 0-10.	0.6	0
63	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. <i>Journal of Gastroenterology</i> , 2017, 52, 444-451.	2.3	96
64	Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1881-1889.	1.1	66
65	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343.	0.9	39
66	A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. <i>American Journal of Gastroenterology</i> , 2017, 112, 1340.	0.2	1
67	Vonoprazan fumarate for the management of acid-related diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1145-1152.	0.9	43
68	The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. <i>European Journal of Internal Medicine</i> , 2017, 37, 19-24.	1.0	184
69	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohnâ€™s disease. A study performed using the LÃ©mann Index. <i>Digestive and Liver Disease</i> , 2017, 49, 175-180.	0.4	25
70	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. <i>Annals of Gastroenterology</i> , 2017, 30, 585-591.	0.4	26
71	Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. <i>Annals of Gastroenterology</i> , 2017, 31, 1-7.	0.4	28
72	Update in gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 172-174.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 318-319.	0.8	1
74	Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 175-183.	0.3	30
75	Complexity and diversity of gastroesophageal reflux disease phenotypes. <i>Minerva Gastroenterology</i> , 2017, 63, 198-204.	0.3	1
76	Etiopathogenesis of rosacea: a prospective study with a three-year follow-up. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 418-423.	0.1	7
77	Barrett's esophagus in 2016: From pathophysiology to treatment. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 190.	0.6	18
78	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 710-711.	0.8	0
79	Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1037-1038.	0.2	1
80	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1081-1086.	0.6	36
81	956 Impairment of Chemical Clearance and Mucosal Integrity Distinguish Hypersensitive Esophagus From Functional Heartburn. <i>Gastroenterology</i> , 2016, 150, S189-S190.	0.6	3
82	Elapazole for the treatment of gastro-esophageal reflux. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2107-2113.	0.9	13
83	Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity. <i>Toxicology and Applied Pharmacology</i> , 2016, 306, 113-119.	1.3	21
84	Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. <i>Autoimmunity Reviews</i> , 2016, 15, 1208-1209.	2.5	10
85	Fecal calprotectin in systemic sclerosis: Light and shade of a promising tool. <i>Autoimmunity Reviews</i> , 2016, 15, 1206-1207.	2.5	2
86	It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, 1364.	0.2	2
87	The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e113-e115.	0.6	43
88	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. <i>American Journal of Gastroenterology</i> , 2016, 111, 1711-1717.	0.2	55
89	Practice guidelines on the use of esophageal manometry – A GISMAD-SIGE-AIGO medical position statement. <i>Digestive and Liver Disease</i> , 2016, 48, 1124-1135.	0.4	82
90	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034.	1.5	35

#	ARTICLE	IF	CITATIONS
91	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1333-1341.	1.5	17
92	Are proton pump inhibitors really so dangerous?. <i>Digestive and Liver Disease</i> , 2016, 48, 851-859.	0.4	66
93	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 40-46.	2.4	222
94	Esophagogastric junction morphology assessment by high resolution manometry in obese patients candidate to bariatric surgery. <i>International Journal of Surgery</i> , 2016, 28, S109-S113.	1.1	21
95	Prognostic role of mean platelet volume in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 409-413.	0.4	16
96	An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic HCV infection and advanced liver disease. <i>Gut</i> , 2016, 65, 183-184.	6.1	0
97	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 719.	0.8	9
98	Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 72.	0.5	26
99	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 292-293.	0.8	2
100	Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 691.	0.9	11
101	Hepatocellular Carcinoma Is the Most Frequent Final Diagnosis of Focal Liver Lesions Identified in a Cross-Sectional Evaluation of Patients with Chronic Liver Disease in Saudi Arabia. <i>Journal of Cancer Research</i> , 2015, 2015, 1-4.	0.7	1
102	Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1856.	2.4	1
103	Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1082-1088.e1.	2.4	121
104	Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2015, 110, 472-473.	0.2	6
105	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. <i>Digestive and Liver Disease</i> , 2015, 47, 1027-1032.	0.4	12
106	Starry Liver: An Unexpected Diagnosis. <i>ACG Case Reports Journal</i> , 2015, 2, 77-78.	0.2	3
107	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 129-130.	0.8	2
108	Esophageal motility abnormalities in gastroesophageal reflux disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 86.	0.6	68

#	ARTICLE	IF	CITATIONS
109	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , 2014, 46, 1043-1046.	0.4	17
110	Gastrointestinal involvement in systemic sclerosis. <i>Presse Medicale</i> , 2014, 43, e279-e291.	0.8	59
111	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. <i>Journal of Gastroenterology</i> , 2014, 49, 1362-1363.	2.3	1
112	Eosinophilic oesophagitis: From physiopathology to treatment. <i>Digestive and Liver Disease</i> , 2013, 45, 871-878.	0.4	25
113	The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1361-1369.	1.5	30
114	The importance of subgrouping refractory NERD patients according to esophageal pH-impedance testing. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 3503-3504.	1.3	0
115	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. <i>Journal of Gastroenterology</i> , 2013, 48, 473-482.	2.3	157
116	Functional testing: pharyngeal pH monitoring and high-resolution manometry. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 226-235.	1.8	12
117	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 278-295.	1.8	17
118	NERD: an umbrella term including heterogeneous subpopulations. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 371-380.	8.2	184
119	Lactulose Breath Test to Assess Oro-cecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 522-529.	1.6	29
120	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 166-186.	1.8	9
121	Dysmotility and reflux disease. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2013, 21, 1.	0.8	21
122	Optimal treatment of laryngopharyngeal reflux disease. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 287-301.	1.1	70
123	Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 11-28.	1.8	6
124	Gastrointestinal motility disorder assessment in systemic sclerosis. <i>Rheumatology</i> , 2013, 52, 1095-1100.	0.9	87
125	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. <i>European Respiratory Journal</i> , 2013, 42, 1322-1331.	3.1	194
126	Therapeutic potential of curcumin in digestive diseases. <i>World Journal of Gastroenterology</i> , 2013, 19, 9256.	1.4	103



#	ARTICLE	IF	CITATIONS
127	Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2013, 19, 5787.	1.4	46
128	Distinction between patients with non-erosive reflux disease and functional heartburn. <i>Annals of Gastroenterology</i> , 2013, 26, 283-289.	0.4	16
129	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 4371.	1.4	59
130	Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012, 32, 1113-1119.	1.9	27
131	The Relevance of Weakly Acidic Reflux in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, e21-e22.	0.6	2
132	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. <i>Journal of Gastroenterology</i> , 2012, 47, 159-168.	2.3	102
133	How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?. <i>World Journal of Gastroenterology</i> , 2012, 18, 4363.	1.4	132
134	Achalasia With Dense Eosinophilic Infiltrate Responds to Steroid Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 1104-1106.	2.4	62
135	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. <i>Digestive and Liver Disease</i> , 2011, 43, 542-547.	0.4	140
136	Overweight is a risk factor for both erosive and non-erosive reflux disease. <i>Digestive and Liver Disease</i> , 2011, 43, 940-945.	0.4	52
137	Microscopic esophagitis and Barrett's esophagus: The histology report. <i>Digestive and Liver Disease</i> , 2011, 43, S319-S330.	0.4	33
138	Barrett's esophagus: proton pump inhibitors and chemoprevention II. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 114-139.	1.8	12
139	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. <i>American Journal of Gastroenterology</i> , 2010, 105, 1053-1061.	0.2	190
140	Observational studies on prescription practices: Interpret with caution. <i>Digestive and Liver Disease</i> , 2010, 42, 348-349.	0.4	1
141	A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2267.	0.1	0
142	Gastroesophageal Reflux and Pulmonary Fibrosis in Scleroderma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 408-413.	2.5	251
143	Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 31-39.	1.4	42
144	Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , 2009, 59, 135-153.	3.1	156

#	ARTICLE	IF	CITATIONS
145	Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment. <i>American Journal of Gastroenterology</i> , 2008, 103, 267-275.	0.2	60
146	The Role of Nonacid Reflux in NERD: Lessons Learned From Impedance-pH Monitoring in 150 Patients off Therapy. <i>American Journal of Gastroenterology</i> , 2008, 103, 2685-2693.	0.2	224
147	Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. <i>American Journal of Gastroenterology</i> , 2008, 103, 1257-1262.	0.2	114
148	Is acid relevant in the genesis of dyspeptic symptoms associated with nonerosive reflux disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 252-254.	0.8	3
149	Thrombocytopenia in liver disease. <i>Current Opinion in Hematology</i> , 2008, 15, 473-480.	1.2	81
150	Functional Heartburn and Non-Erosive Reflux Disease. <i>Digestive Diseases</i> , 2007, 25, 172-174.	0.8	49
151	Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1602-1606.	1.1	8
152	A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1904-1909.	1.1	31
153	Proton Pump Inhibitor Failure: Why Does It Occur and How Can It Be Managed?. <i>Digestion</i> , 2006, 73, 215-217.	1.2	11
154	Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group. <i>American Journal of Gastroenterology</i> , 2005, 100, 2299-2306.	0.2	192
155	Optimizing Symptom Relief and Preventing Complications in Adults with Gastro-Oesophageal Reflux Disease. <i>Digestion</i> , 2004, 69, 9-16.	1.2	21
156	Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. <i>Digestive Diseases and Sciences</i> , 1998, 43, 459-463.	1.1	18
157	Increased prevalence of <i>Helicobacter pylori</i> infection in females treated with dopaminergic drugs for hyperprolactinaemia. <i>Clinical Endocrinology</i> , 1998, 48, 373-374.	1.2	2
158	Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 152-157.	1.8	21
159	Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 700-705.	0.5	135
160	A Comparison of Five Maintenance Therapies for Reflux Esophagitis. <i>New England Journal of Medicine</i> , 1995, 333, 1106-1110.	13.9	542
161	Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1473-1482.	1.1	5
162	Variability in individual response to various doses of omeprazole. <i>Digestive Diseases and Sciences</i> , 1994, 39, 161-168.	1.1	38

#	ARTICLE	IF	CITATIONS
163	Twenty-four-Hour Control of Gastric Acidity by Twice-Daily Doses of Placebo, Nizatidine 150 mg, Nizatidine 300 mg, and Ranitidine 300 mg. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 70-74.	1.0	8
164	Duration of Acid Suppression in H <sub>2</sub> -Antagonist Nonresponders. <i>Digestion</i> , 1992, 51, 185-192.	1.2	6
165	Comparison of the Effects of Placebo, Ranitidine, Famotidine and Nizatidine on Intra-gastric Acidity by Means of Continuous pH Recording. <i>Digestion</i> , 1989, 42, 1-6.	1.2	25